Shridar Ganesan

Shridar Ganesan

Rutgers, The State University of New Jersey

H-index: 67

North America-United States

Contact Shridar Ganesan

About Shridar Ganesan

Shridar Ganesan, With an exceptional h-index of 67 and a recent h-index of 48 (since 2020), a distinguished researcher at Rutgers, The State University of New Jersey, specializes in the field of DNA repair, Cancer genomics, Breast Cancer.

His recent articles reflect a diverse array of research interests and contributions to the field:

SOX9-dependent immune microenvironment remodeling drives KRAS-induced lung adenocarcinoma progression

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC

Recurrence‐free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials

Abstract B075: Developing a population-based study of South Asian American breast cancer survivors in New Jersey

OA18. 06 SOX9 Drives KRAS-Induced Lung Adenocarcinoma Progression Through Suppression of Anti-Tumor Immunity

Promoting informed approaches in precision oncology and clinical trial participation for Black patients with cancer: Community‐engaged development and pilot testing of a …

Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy

Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study

Shridar Ganesan Information

University	Rutgers, The State University of New Jersey
Position	Professor of Medicine, Rutgers Cancer Institute of New Jersey
Citations(all)	34250
Citations(since 2020)	14459
Cited By	23806
hIndex(all)	67
hIndex(since 2020)	48
i10Index(all)	154
i10Index(since 2020)	128
Email	Access Email
University Profile Page	Rutgers, The State University of New Jersey
Google Scholar	View Google Scholar Profile

Shridar Ganesan Skills & Research Interests

DNA repair

Cancer genomics

Breast Cancer

Top articles of Shridar Ganesan

SOX9-dependent immune microenvironment remodeling drives KRAS-induced lung adenocarcinoma progression

Cancer Research

2024/3/22

Hua Zhong

H-Index: 13

Shridar Ganesan

H-Index: 43

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC

Nature communications

2024/1/8

Shridar Ganesan

H-Index: 43

Shantenu Jha

H-Index: 22

Isaac Kim

H-Index: 15

Vishal Kothari

H-Index: 14

Recurrence‐free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials

2024/1

H Richard Alexander

H-Index: 37

Patrick M Boland

H-Index: 17

Shridar Ganesan

H-Index: 43

Abstract B075: Developing a population-based study of South Asian American breast cancer survivors in New Jersey

Cancer Epidemiology, Biomarkers & Prevention

2023/12/1

Nur Zeinomar

H-Index: 9

Antoinette Stroup

H-Index: 32

Shridar Ganesan

H-Index: 43

Hao Liu

H-Index: 30

OA18. 06 SOX9 Drives KRAS-Induced Lung Adenocarcinoma Progression Through Suppression of Anti-Tumor Immunity

Journal of Thoracic Oncology

2023/11/1

Promoting informed approaches in precision oncology and clinical trial participation for Black patients with cancer: Community‐engaged development and pilot testing of a …

Cancer

2023/10/13

Shridar Ganesan

H-Index: 43

Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy

bioRxiv

2023/10/4

Zhihua Kang

H-Index: 11

Pan Fu

H-Index: 8

Hui Ma

H-Index: 13

Tao Li

H-Index: 10

Kevin Lu

H-Index: 15

Juan Liu

H-Index: 49

Vasudeva Ginjala

H-Index: 10

Ming Guan

H-Index: 2

Shridar Ganesan

H-Index: 43

Bing Xia

H-Index: 31

Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study

JCO Precision Oncology

2023/9

Diep Nguyen

H-Index: 7

Shridar Ganesan

H-Index: 43

Clinical efficacy of PARP inhibitors in breast cancer

2023/7

Shridar Ganesan

H-Index: 43

SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity

Oncogene

2023/5/31

Hua Zhong

H-Index: 13

Wen Lu

H-Index: 3

Yong Tang

H-Index: 7

Yong Wei

H-Index: 13

Jian Cao

H-Index: 16

Jessie Yanxiang Guo

H-Index: 17

Yibin Kang

H-Index: 65

Shridar Ganesan

H-Index: 43

Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer

medRxiv

2023/3/10

Akshada Sawant

H-Index: 4

Hua Ke

H-Index: 19

Fuqian Shi

H-Index: 22

Ying Chen

H-Index: 6

Jessie Yanxiang Guo

H-Index: 17

Maria Gomez

H-Index: 10

Maria Ibrahim

H-Index: 1

Shridar Ganesan

H-Index: 43

Xiaoyang Su

H-Index: 19

Subhajyoti De

H-Index: 29

Chang S Chan

H-Index: 17

Eileen White

H-Index: 62

Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

NPJ Breast Cancer

2023/5/17

Yuli Chen

H-Index: 18

Haojia Li

H-Index: 2

Andrew Janowczyk

H-Index: 17

Cheng Lu

H-Index: 1

Shridar Ganesan

H-Index: 43

Michael D Feldman

H-Index: 59

Pingfu Fu

H-Index: 35

Anant Madabhushi

H-Index: 58

133P Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with early-stage breast cancer (eBC)

ESMO Open

2023/5/1

M George

H-Index: 2

Truncated FGFR2-a clinically actionable oncogene in multiple cancers

Cancer Research

2023/4/4

Shridar Ganesan

H-Index: 43

Abstract P6-11-05: Carnitine palmitoyltransferase 1A (CPT1A) mediates therapeutic response to endocrine therapy in estrogen receptor positive breast cancer

Cancer Research

2023/3/1

Shaimaa Hussein

H-Index: 8

Shridar Ganesan

H-Index: 43

Abstract P5-07-08: Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 …

Cancer Research

2023/3/1

Shridar Ganesan

H-Index: 43

Bruce G Haffty

H-Index: 44

Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with …

Cancer Research

2023/3/1

Yuli Chen

H-Index: 18

Haojia Li

H-Index: 2

Cheng Lu

H-Index: 1

Andrew Janowczyk

H-Index: 17

German Corredor

H-Index: 6

Shridar Ganesan

H-Index: 43

Michael Feldman

H-Index: 18

Pingfu Fu

H-Index: 35

Lajos Pusztai

H-Index: 72

Daniel Hayes

H-Index: 9

Anant Madabhushi

H-Index: 58

Evaluation of inequities in cancer treatment delay or discontinuation following SARS-CoV-2 infection

JAMA Network Open

2023/1/3

Yong Lin

H-Index: 12

Shridar Ganesan

H-Index: 43

A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP# 8850

Oncotarget

2023

Jyoti Malhotra

H-Index: 17

Shridar Ganesan

H-Index: 43

Jiadong Li

H-Index: 9

Suzie Chen

H-Index: 23

Abstract C103: Inequities in timely cancer treatment after testing positive for COVID-19: Findings from the ASCO Survey on COVID-19 in Oncology (ASCO) Registry

2023/1/1

Yong Lin

H-Index: 12

Shridar Ganesan

H-Index: 43

See List of Professors in Shridar Ganesan University(Rutgers, The State University of New Jersey)

academic-engine

Useful Links

List of top 50 universities

List of top 100 universities

List of top 500 universities

Find Professors Email

Find Universities Email

CUFinder Academic Engine